Cobimetinib is designed to be used with another Roche drug called Zelboraf for patients with tumours that have a mutation in a gene known as BRAF that allows melanoma cells to grow.
When used in this way, the drug helped people with advanced melanoma live longer without their disease worsening, results of a Phase III trial showed in July.